The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.
This distinction between true value and value traps can challenge even the most skilled investors. Luckily for you, we started StockStory to help you uncover exceptional companies. That said, here is one value stock with strong fundamentals and two best left ignored.
Two Value Stocks to Sell:
American Express Global Business Travel (GBTG)
Forward P/S Ratio: 0.9x
Originally spun off from American Express in 2014 but maintaining the Amex GBT brand, Global Business Travel Group (NYSE: GBTG) provides end-to-end business travel and expense management solutions, connecting corporate clients with travel suppliers and offering specialized software services.
Why Do We Steer Clear of GBTG?
- Muted 8.9% annual revenue growth over the last two years shows its demand lagged behind its software peers
- Gross margin of 60.1% reflects its relatively high servicing costs
- Operating margin was unchanged over the last year, suggesting it failed to gain leverage on its fixed costs
American Express Global Business Travel’s stock price of $5.76 implies a valuation ratio of 0.9x forward price-to-sales. To fully understand why you should be careful with GBTG, check out our full research report (it’s free).
Integra LifeSciences (IART)
Forward P/E Ratio: 4.5x
Founded in 1989 as a pioneer in regenerative medicine technology, Integra LifeSciences (NASDAQ: IART) develops and manufactures medical technologies for neurosurgery, wound care, and surgical reconstruction, including regenerative tissue products and surgical instruments.
Why Are We Out on IART?
- Organic revenue growth fell short of our benchmarks over the past two years and implies it may need to improve its products, pricing, or go-to-market strategy
- Free cash flow margin shrank by 19 percentage points over the last five years, suggesting the company is consuming more capital to stay competitive
- 6× net-debt-to-EBITDA ratio makes lenders less willing to extend additional capital, potentially necessitating dilutive equity offerings
Integra LifeSciences is trading at $10.72 per share, or 4.5x forward P/E. Check out our free in-depth research report to learn more about why IART doesn’t pass our bar.
One Value Stock to Watch:
Keurig Dr Pepper (KDP)
Forward P/E Ratio: 12.3x
Born out of a 2018 merger between Keurig Green Mountain and Dr Pepper Snapple, Keurig Dr Pepper (NASDAQ: KDP) is a consumer staples powerhouse boasting a portfolio of beverages including sodas, coffees, and juices.
Why Does KDP Stand Out?
- Products are reaching more households as its unit sales averaged 4.8% growth over the past two years
- Economies of scale give it negotiating power with retailers and suppliers as well as fixed cost leverage when sales grow
- Demand for the next 12 months is expected to accelerate above its three-year trend as Wall Street forecasts robust revenue growth of 72.3%
At $28.25 per share, Keurig Dr Pepper trades at 12.3x forward P/E. Is now the right time to buy? Find out in our full research report, it’s free.
Stocks We Like Even More
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
